Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.
Saved in:
| Title: | Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022. |
|---|---|
| Authors: | Milder TY; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.; Department of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, Australia.; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia.; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, Australia.; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia., Lin J; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Pearson SA; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., Greenfield JR; Department of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, Australia.; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, Australia.; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia., Day RO; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia.; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia., Stocker SL; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia.; School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia.; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Australia., Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia.; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia., Falster MO; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia., de Oliveira Costa J; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. |
| Source: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2025 Jan; Vol. 91 (1), pp. 117-126. Date of Electronic Publication: 2024 Sep 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2125 |
|---|---|
| DOI: | 10.1111/bcp.16231 |
